Moreover, analysis of several cancer immunotherapy-related metrics (e.g., TIDE, MSI score, TMB, CD274 expression, CD8 infiltration, IFNγ expression) revealed significant variability in PIGF’s predictive performance across different datasets, with high predictive accuracy observed in glioblastoma and certain melanoma datasets (Figure 8F). This evidence concerns the gene CD8A and glioblastoma.